Machine learning predicts stem cell transplant response in severe scleroderma.
Jennifer M FranksViktor MartyanovYue WangTammara A WoodAshley PinckneyLeslie J CroffordLynette Keyes-ElsteinDaniel E FurstEllen GoldmuntzMaureen D MayesPeter McSweeneyRichard A NashKeith M SullivanMichael L WhitfieldPublished in: Annals of the rheumatic diseases (2020)
Participants from the fibroproliferative subset showed the most significant long-term benefit from HSCT compared with CYC. This study suggests that intrinsic subset stratification of patients may be used to identify patients with SSc who receive significant benefit from HSCT.